Key result
On-ticagrelor VASP index shows no link to bleeding or thrombotic events in ACS patients post-PCI.
Why the study?
While on-thienopyridine platelet reactivity correlates with thrombotic and bleeding risks in ACS patients undergoing PCI, the relationship between on-ticagrelor platelet reactivity and clinical outcomes remained unanalyzed.
Does on-ticagrelor platelet reactivity measured by VASP index predict bleeding or thrombotic outcomes in ACS patients undergoing PCI?
Observational
Yes
Does on-ticagrelor platelet reactivity measured by VASP index predict bleeding or thrombotic outcomes in ACS patients undergoing PCI?
On-ticagrelor platelet reactivity measured by the VASP index does not correlate with bleeding or thrombotic events in ACS patients undergoing PCI, suggesting it should not be used as a surrogate endpoint.
Answers are grounded in this paper and cite their sources.
Does not support VASP monitoring to predict events in ACS-PCI on ticagrelor; leaves open whether platelet reactivity testing adds value beyond standard care.
BACKGROUND: A strong association between on-thienopyridine platelet reactivity (PR) and the risk of both thrombotic and bleeding events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) has been demonstrated. However, no study has analyzed the relationship between on-ticagrelor PR and clinical outcome in this clinical setting. OBJECTIVES: We aimed to investigate the relationship between on-ticagrelor PR, assessed by the vasodilator-stimulated phosphoprotein (VASP) index, and clinical outcome in patients with ACS undergoing PCI. METHODS: We performed a prospective, multicenter, observational study of patients undergoing PCI for ACS. PR was measured using the VASP index following ticagrelor loading dose. The primary study endpoint was the rate of Bleeding Academic Research Consortium (BARC) type ≥2 at 1 year. The key secondary endpoint was the rate of major adverse cardiovascular events (MACE) defined as the composite of cardiovascular death, myocardial infarction, stroke, and urgent revascularization. RESULTS: = 0.56, respectively). No relationship between PR and outcomes was observed, neither when PR was analyzed quantitatively nor when it was analyzed qualitatively (low on-treatment PR [LTPR] vs. no LTPR). CONCLUSION: On-ticagrelor PR measured by the VASP was not associated with bleeding or thrombotic events in ACS patients undergoing PCI. PR measured by the VASP should not be used as a surrogate endpoint in studies on ticagrelor.
No takes yet. Share an insight, caveat, or question.
Laine et al. (2020) conducted an observational in Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). On-ticagrelor platelet reactivity (PR) vs. No low on-treatment PR (LTPR) was evaluated on Rate of Bleeding Academic Research Consortium (BARC) type ≥2 at 1 year. On-ticagrelor platelet reactivity measured by the VASP index was not associated with bleeding or thrombotic events in ACS patients undergoing PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: